Incannex Healthcare Inc Dossier
Qualitative Analysis
Business overview
Incannex Healthcare Inc. (Nasdaq: IXHL) is a clinical-stage biopharmaceutical company specializing in the development of innovative combination therapies and therapeutic regimens. The company's proprietary pipeline leverages smart drug combinations pairing synthetic cannabinoids or psychedelics with established active pharmaceutical ingredients to target underlying biological pathways associated with chronic conditions. Its lead clinical programs include IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide designed to act synergistically for the treatment of Obstructive Sleep Apnea (OSA); IHL-675A, a combination of cannabidiol (CBD) and hydroxychloroquine sulfate targeting inflammatory conditions such as rheumatoid arthritis; and PSX-001, an oral synthetic psilocybin treatment administered alongside psychotherapy for Generalized Anxiety Disorder (GAD).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A crossover dose-optimization study evaluating IHL-42X (dronabinol and acetazolamide) to refine dosing profiles and de-risk the planned Phase 3 program for obstructive sleep apnea.
Expected impact: Optimizes physiological outcomes and patient-reported quality of life metrics to support FDA registration pathways.
Establishment of a Clinical Advisory Board (CAB) comprising leading experts in psychiatry and neurobiology to guide the clinical and regulatory development of PSX-001.
Expected impact: Strengthens scientific rigor, trial design, and regulatory engagement strategies as PSX-001 prepares for Phase 2b trials.
Execution of capital discipline measures including a 1-for-30 reverse stock split, cancellation of outstanding Series A warrants, and authorization of a $20 million share repurchase program.
Expected impact: Eliminates potential dilution, maintains Nasdaq listing compliance, and optimizes shareholder value.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Incannex joined the AASM Foundation's Corporate Recognition Program and will sponsor a Focused Projects Grant for Junior Investigators dedicated to sleep apnea treatment.
Terms: Sponsorship of a dedicated research grant to be awarded in 2026.
A 50:50 joint venture established to expand local clinical access to psychedelic-assisted psychotherapies in Australia, leveraging Clarion Clinics' operational model.
Terms: 50:50 profit and cost-sharing structure.